Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen : Notice of Lead Plaintiff Deadline for Shareholders in the Ocugen, Inc. Class Action Lawsuit

06/18/2021 | 05:07pm EDT

Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Ocugen, Inc. (NASDAQ:OCGN) securities between February 2, 2021 and June 10, 2021, inclusive (the “Class Period”). The case is captioned Nicanor v. Ocugen, Inc., No. 21-cv-02725, and charges Ocugen and certain of its executives with violations of the Securities Exchange Act of 1934.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Ocugen securities during the Class Period to seek appointment as lead plaintiff in the Ocugen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Ocugen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Ocugen class action lawsuit. An investor’s ability to share in any potential future recovery of the Ocugen class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Ocugen class action lawsuit or have questions concerning your rights regarding the Ocugen class action lawsuit, please provide your information here or contact counsel, J.C. Sanchez of Robbins Geller, at 800/449-4900 or 619/231-1058 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Ocugen class action lawsuit must be filed with the court no later than August 17, 2021.

Ocugen is a biopharmaceutical company focused on developing gene therapies to cure blindness and developing a vaccine for COVID-19. On February 2, 2021, Ocugen announced an agreement with Bharat Biotech International Limited, a biotechnology company headquartered in Hyderabad, India, in which Ocugen obtained an exclusive right and license to grant sublicenses, to develop, manufacture, and commercialize COVAXIN™, an advanced stage whole-virion inactivated vaccine candidate/product for the prevention of COVID-19 in humans in the United States of America. Ocugen further announced that Ocugen “will be responsible for clinical development, regulatory approval (including [Emergency Use Authorization (“EUA”)] and commercialization for the US market.”

The Ocugen class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the information that Ocugen submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an EUA; (ii) Ocugen would not file an EUA with the FDA; and (iii) as a result, Ocugen’s financial statements, as well as defendants’ statements about Ocugen’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On June 10, 2021, Ocugen issued a press release announcing that it would pursue a biologics license application (“BLA”) with the FDA instead of the previously announced EUA. In doing so, Ocugen revealed that “[t]he FDA provided feedback to Ocugen regarding the Master File the Company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data. Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission. The Company anticipates that data from an additional clinical trial will be required to support the submission.” On this news, the price of Ocugen’s stock fell more than 28%, damaging investors.

With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs’ firm. Please visit http://www.rgrdlaw.com for more information.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.


ę Business Wire 2021
All news about OCUGEN, INC.
07/26OCGN INVESTOR NOTICE : ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. ..
PR
07/23DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
07/21OCUGEN : Levi & Korsinsky, LLP
AQ
07/20OCUGEN : The Law Offices of Frank R. Cruz Announces the Filing of a Securities C..
PR
07/20OCUGEN, INC. : Other Events (form 8-K)
AQ
07/19VIRGIN GALACTIC : The Law Offices of Vincent Wong
AQ
07/16OCUGEN : Pomerantz Law Firm Announces the Filing of a Class Action Against Ocuge..
PR
07/16OCUGEN INC : .áAnnounces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
07/15OCUGEN : Announces Initiation of Rolling Submission to Health Canada for COVAXIN..
PU
07/15OCUGEN, INC. : Other Events (form 8-K)
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -45,5x
Yield 2021 -
Capitalization 1 352 M 1 352 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 9,96x
Nbr of Employees 15
Free-Float 97,5%
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 6,82 $
Average target price 7,90 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.272.68%1 352
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.38.02%47 396
CELLTRION, INC.-26.46%31 265
SEAGEN INC.-18.34%25 955